Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22957708 | 0.88 | NTRK1 (0.42) | NTRK1ALDH1A1KCNH2HTR2ASLC6A4 | |
| SCHEMBL22957928 | 0.85 | NTRK1 (0.41) | NTRK1ALDH1A1KCNH2HTR2ASLC6A4 | |
| SCHEMBL22957698 | 0.84 | SLC6A4 (0.56) | NTRK1ALDH1A1KCNH2HTR2ASLC6A4 | |
| SCHEMBL22957693 | 0.84 | ATM (0.46) | CCR5ALDH1A1RAB9ASLC6A4 | |
| SCHEMBL22957865 | 0.82 | KCNH2 (0.42) | CCR5ALDH1A1RAB9AKCNH2HTR2A | |
| SCHEMBL14012652 | 0.82 | KCNH2 (0.52) | NTRK1CCR5ALDH1A1RAB9AKCNH2 | |
| SCHEMBL22957926 | 0.78 | NTRK1 (0.43) | NTRK1ALDH1A1KCNH2HTR2ASLC6A4 | |
| SCHEMBL28613921 | 0.76 | ALDH1A1 (0.44) | NTRK1ALDH1A1KCNH2HTR2ASLC6A4 | |
| SCHEMBL24180218 | 0.76 | PPARG (0.40) | NTRK1ALDH1A1RAB9AMRGPRX1CYP1A2 | |
| SCHEMBL22390440 | 0.76 | NTRK1 (0.40) | NTRK1ALDH1A1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | NTRK1 448/4885CCR5 2773/4885ALDH1A1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.